EP3125891A4 - Novel hdmx inhibitors and their use for cancer treatment - Google Patents
Novel hdmx inhibitors and their use for cancer treatment Download PDFInfo
- Publication number
- EP3125891A4 EP3125891A4 EP15772336.2A EP15772336A EP3125891A4 EP 3125891 A4 EP3125891 A4 EP 3125891A4 EP 15772336 A EP15772336 A EP 15772336A EP 3125891 A4 EP3125891 A4 EP 3125891A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- hdmx
- inhibitors
- novel
- cancer treatment
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/02—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with only hydrogen, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9
- C07D219/12—Amino-alkylamino radicals attached in position 9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461972514P | 2014-03-31 | 2014-03-31 | |
| PCT/US2015/023462 WO2015153535A1 (en) | 2014-03-31 | 2015-03-31 | Novel hdmx inhibitors and their use for cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3125891A1 EP3125891A1 (en) | 2017-02-08 |
| EP3125891A4 true EP3125891A4 (en) | 2017-08-09 |
Family
ID=54241190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP15772336.2A Withdrawn EP3125891A4 (en) | 2014-03-31 | 2015-03-31 | Novel hdmx inhibitors and their use for cancer treatment |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10183912B2 (hu) |
| EP (1) | EP3125891A4 (hu) |
| JP (1) | JP6483804B2 (hu) |
| CA (1) | CA2944462A1 (hu) |
| WO (1) | WO2015153535A1 (hu) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10767182B2 (en) * | 2014-11-14 | 2020-09-08 | Vib Vzw | Direct and selective inhibition of MDM4 for treatment of cancer |
| EP3288547B1 (en) | 2015-04-27 | 2023-06-07 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Egr1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions |
| WO2019094788A1 (en) * | 2017-11-09 | 2019-05-16 | Georgetown University | Compounds for inhibiting ly6k and methods of using same |
| WO2023116397A1 (zh) * | 2021-12-25 | 2023-06-29 | 珞达生物医药(苏州)有限公司 | 固有免疫激活药物及其用途 |
| CN114805205A (zh) * | 2022-04-27 | 2022-07-29 | 郑州大学 | 一种吖啶类化合物及其制备方法和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001064645A2 (en) * | 2000-03-01 | 2001-09-07 | Orion Corporation | Derivatives of quinoline as alpha-2 antagonists |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5651457A (en) * | 1979-09-14 | 1981-05-09 | Dev Finance | Antitumoral compound and its manufacture |
| US5939428A (en) * | 1996-06-20 | 1999-08-17 | National Health Research Institutes | Alkyl N- 3-(acridin-9-yl)amino-5-hydroxymethyl! phenylcarbamates |
| US7232663B2 (en) * | 2005-07-13 | 2007-06-19 | The University Of Wyoming | Assays employing novel substrates for measuring P450-mediated N-dealkylation |
| WO2008010984A2 (en) * | 2006-07-17 | 2008-01-24 | The Trustees Of The University Of Pennsylvania | Acridine activation of p53 and uses thereof |
| US20080161324A1 (en) * | 2006-09-14 | 2008-07-03 | Johansen Lisa M | Compositions and methods for treatment of viral diseases |
| US20120220537A1 (en) * | 2009-11-01 | 2012-08-30 | Ariel-University Research And Development Company Ltd. | 9-aminoacridine derivatives, their preparation and uses |
-
2015
- 2015-03-31 EP EP15772336.2A patent/EP3125891A4/en not_active Withdrawn
- 2015-03-31 CA CA2944462A patent/CA2944462A1/en not_active Abandoned
- 2015-03-31 WO PCT/US2015/023462 patent/WO2015153535A1/en active Application Filing
- 2015-03-31 JP JP2017503776A patent/JP6483804B2/ja not_active Expired - Fee Related
- 2015-03-31 US US15/300,871 patent/US10183912B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001064645A2 (en) * | 2000-03-01 | 2001-09-07 | Orion Corporation | Derivatives of quinoline as alpha-2 antagonists |
Non-Patent Citations (11)
| Title |
|---|
| AGNIESZKA WR?BLEWSKA ET AL: "Tautomerism of 9-acridinamines substituted at the exocyclic nitrogen atom in view of computational predictions and experimental findings", CHEMICAL PHYSICS, vol. 303, no. 3, 1 August 2004 (2004-08-01), NL, pages 301 - 308, XP055386426, ISSN: 0301-0104, DOI: 10.1016/j.chemphys.2004.06.025 * |
| DENNY W A ET AL: "Potential antitumor gents. 26. Quantitative relationships between experimental antitumor activity, toxicity, and structure for the general class of 9-anilinoacridine antitumor agents", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 25, no. 3, 1 March 1982 (1982-03-01), pages 276 - 315, XP002081503, ISSN: 0022-2623, DOI: 10.1021/JM00345A015 * |
| HUA GAO ET AL: "Quantitative structure-activity relationships (QSAR) for 9-anilinoacridines: a comparative analysis", CHEMICO-BIOLOGICAL INTERACTIONS., vol. 116, no. 3, 1 November 1998 (1998-11-01), IR, pages 157 - 180, XP055386439, ISSN: 0009-2797, DOI: 10.1016/S0009-2797(98)00085-4 * |
| KAZUNORI KAWAMURA ET AL: "In Vivo Evaluation of Limiting Brain Penetration of Probes for [alpha] 2C -Adrenoceptor Using Small-Animal Positron Emission Tomography", ACS CHEMICAL NEUROSCIENCE, vol. 1, no. 7, 21 July 2010 (2010-07-21), pages 520 - 528, XP055026087, ISSN: 1948-7193, DOI: 10.1021/cn1000364 * |
| KLOPMAN G ET AL: "COMPUTER-AUTOMATED STRUCTURE EVALUATION OF ANTILEUKEMIC 9-ANILINOACRIDINES", MOLECULAR PHARMACOLOGY, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 31, no. 4, 1 January 1987 (1987-01-01), pages 457 - 476, XP000926707, ISSN: 0026-895X * |
| LOZA-MEJIA M A ET AL: "Molecular modeling of tricyclic compounds with anilino substituents and their intercalation complexes with DNA sequences", JOURNAL OF MOLECULAR GRAPHICS AND MODELLING, ELSEVIER SCIENCE, NEW YORK, NY, US, vol. 27, no. 8, 1 June 2009 (2009-06-01), pages 900 - 907, XP026144028, ISSN: 1093-3263, [retrieved on 20090212], DOI: 10.1016/J.JMGM.2009.02.001 * |
| MANUEL J ET AL: "9-ANILINOACRIDINES AS POTENTIAL ANTILEISHMANIAL AGENTS", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 37, no. 5, 1 May 1993 (1993-05-01), pages 991 - 996, XP001013336, ISSN: 0066-4804 * |
| P. CHAVALITSHEWINKOON-PETMITR ET AL: "Inhibitory effects of 9-anilinoacridines on Plasmodium falciparum gametocytes", TROPICAL MEDICINE AND INTERNATIONAL HEALTH., vol. 6, no. 1, 1 January 2001 (2001-01-01), GB, pages 42 - 45, XP055386437, ISSN: 1360-2276, DOI: 10.1046/j.1365-3156.2001.00656.x * |
| RF MARTIN ET AL: "Synthesis and N.M.R. Spectra of Substituted Aminoiodoacridines", AUSTRALIAN JOURNAL OF CHEMISTRY: AN INTERNATIONAL JOURNAL FOR CHEMICAL SCIENCE, vol. 32, no. 12, 1 January 1979 (1979-01-01), AU, pages 2637, XP055386419, ISSN: 0004-9425, DOI: 10.1071/CH9792637 * |
| See also references of WO2015153535A1 * |
| WERBOVETZ K A ET AL: "Cleavable complex formation in Leishmania chagasi treated with anilinoacridines", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 65, no. 1, 1 May 1994 (1994-05-01), pages 1 - 10, XP025440995, ISSN: 0166-6851, [retrieved on 19940501], DOI: 10.1016/0166-6851(94)90110-4 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3125891A1 (en) | 2017-02-08 |
| US20170022166A1 (en) | 2017-01-26 |
| CA2944462A1 (en) | 2015-10-08 |
| JP2017516842A (ja) | 2017-06-22 |
| JP6483804B2 (ja) | 2019-03-13 |
| WO2015153535A1 (en) | 2015-10-08 |
| US10183912B2 (en) | 2019-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201607415B (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| EP3174538A4 (en) | Methods and therapeutic combinations for treating tumors | |
| EP3227317A4 (en) | Methods and compositons for treating cancer | |
| EP3134436A4 (en) | Treatment of h-ras-driven tumors | |
| EP3110443A4 (en) | Combination method for treatment of cancer | |
| EP3200815A4 (en) | Methods and compositions for treating cancer | |
| EP3177292A4 (en) | Compounds and methods for treating cancer | |
| IL248767B (en) | Trimethoxyphenyl-benzaimidazole compounds for cancer treatment | |
| EP3193905A4 (en) | Methods of treating cervical cancer | |
| EP3157336A4 (en) | Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer | |
| EP3202909A4 (en) | Cancer specific-splicing ribozyme and use thereof | |
| EP3164394A4 (en) | Gls1 inhibitors for treating disease | |
| EP3119390A4 (en) | Methods of treating cancer | |
| EP3152195A4 (en) | Mth1 inhibitors for treatment of cancer | |
| EP3099297A4 (en) | Novel methods for treating cancer | |
| EP3106097A4 (en) | Treatment instrument | |
| EP3185910A4 (en) | Methods and compositions for the treatment of cancer | |
| EP3119426A4 (en) | Methods and materials for treating cancer | |
| EP3119427A4 (en) | Methods and materials for treating cancer | |
| EP3125891A4 (en) | Novel hdmx inhibitors and their use for cancer treatment | |
| EP3106112A4 (en) | Treatment instrument | |
| EP3363461A4 (en) | ANTI-CD43 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER | |
| EP3337784A4 (en) | USE OF UREIDOMUSTIN (BO-1055) IN THE TREATMENT OF CANCER | |
| EP3240778A4 (en) | Methods and agents for treating disease | |
| EP3106119A4 (en) | Treatment instrument |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20161003 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20170710 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/473 20060101AFI20170704BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20181002 |